BlossomHill Therapeutics (NASDAQ:BLSM) Stock Price Up 5.8% – What’s Next?

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM)’s share price traded up 5.8% on Wednesday . The company traded as high as $23.60 and last traded at $23.46. 35,999 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 197,364 shares. The stock had previously closed at $22.17.

Analyst Ratings Changes

Several research firms have recently commented on BLSM. Zacks Research raised shares of BlossomHill Therapeutics to a “hold” rating in a research report on Wednesday, September 2nd. Wall Street Zen upgraded BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. HC Wainwright initiated coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They set a “buy” rating and a $35.00 price objective for the company. Lifesci Capital started coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price objective for the company. Finally, JPMorgan Chase & Co. started coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.20.

BlossomHill Therapeutics Stock Performance

Insider Buying and Selling

In other BlossomHill Therapeutics news, Director Carl Gordon purchased 625,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the director owned 2,714,279 shares of the company’s stock, valued at $43,428,464. The trade was a 29.91% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bihua Chen purchased 312,500 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the acquisition, the director directly owned 3,614,034 shares of the company’s stock, valued at $57,824,544. This trade represents a 9.47% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 1,573,900 shares of company stock valued at $25,181,900 over the last quarter.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.